This week's View focuses on the coronavirus disease 2019 (COVID-19) resources on ACC.org, including recently published articles on the impact of bamlanivimab with or without etesevimab on severe acute respiratory syndrome coronavirus 2 viral load in mild to moderate COVID-19, the current state of COVID-19 vaccines, and the rate of anaphylactic reactions following one's first dose of the Pfizer-BioNTech COVID-19 vaccine.

Subscribe on Apple Podcasts | Subscribe on Google Play

Clinical Topics: Cardiovascular Care Team, Congenital Heart Disease and Pediatric Cardiology, COVID-19 Hub, Diabetes and Cardiometabolic Disease, Dyslipidemia, Prevention, Vascular Medicine, Congenital Heart Disease, CHD and Pediatrics and Arrhythmias, CHD and Pediatrics and Prevention, CHD and Pediatrics and Quality Improvement, Lipid Metabolism, Novel Agents

Keywords: EaglesEyeView, COVID-19, ACC COVID-19 Podcast, Coronavirus, Coronavirus Infections, severe acute respiratory syndrome coronavirus 2, Pandemics, Adenoviruses, Human, Adolescent, Adverse Drug Reaction Reporting Systems, Anaphylaxis, Angioedema, Antibodies, Antibodies, Monoclonal, Critical Care, Emergency Service, Hospital, Exanthema, Immunologic Deficiency Syndromes, Influenza Vaccines, Lipids, Nanoparticles, Outpatients, Patient Discharge, Pharmaceutical Preparations, Primary Prevention, Risk Factors, RNA, Messenger, Severe Acute Respiratory Syndrome, Spike Glycoprotein, Coronavirus, Vaccination, Viral Load, Heart Defects, Congenital, Dyslipidemias

< Back to Listings